GRCL News and Press, Gracell Biotechnologies Inc. From 03/09/21

Reported interim readouts for lead CAR-T product candidates: FasTCAR-enabled dual-targeting BCMA/CD19 autologous CAR-T product candidate GC012F for the treatment of multiple myeloma and TruUCAR-enabled CD7-directed CAR-T product candidate GC027 for the treatment of T-ALL Completed...

Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021 PR Newswire SUZHOU and SHANGHAI, China , Feb. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage bi...

Point Roberts, WA and Delta, BC - February 5, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech, Crypto, Cannabis, Tech, Gaming, Pets and Automotive. Toda...

Gracell Biotechnologies (GRCL) has dropped ~3.0% over the past two-week period. However, the stock has jumped 22.1% today after Wall Street analysts weighed in on the stock with a string of buy ratings as the company’s IPO quiet period ends.Gracell made a debut at Wells Fargo...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The stock market tries to reset after its worst week since October with even popular stocks like Apple (NASDAQ:AAPL) and...

The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion. Canadian digital service provider TELUS International plans to raise $800 million at a $6.4 billion market cap. Street research is expected for Cullinan Management and Gra...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Adagene, a Suzhou immunotherapy company, plans to raise up to $125 million in a US IPO on the NASDAQ Exchange. TenNor Therapeutics (Suzhou), a company that develops dual-action antibiotics, announced a research collaboration with Janssen Pharma that will use TenNor's drug conjugation ...

National Medical Products Administration in China has signed off Gracell Biotechnologies' ([[GRCL]] -2.1%) investigational new drug application to study GC019F, a FasTCAR-enabled chimeric antigen receptor ((CAR))-T therapy in patients with relapsed or refractory adult B-cell acute lympho...

Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL PR Newswire SUZHOU and SHANGHAI, China , Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (...